Skip to main content
OpenTrials
Completed

NCT Number: NCT05065762

Measuring the Treatment Preferences of Participants in Japan With Moderate-to-Severe Psoriasis (PsO) Using Discrete Choice Experiment

The purpose of this observational study is to identify and weight the treatment attributes from the moderate-to-severe Psoriasis (PsO) patients' perspective in Japan.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Psoriasis Skin Diseases Skin Diseases, Papulosquamous Skin and Connective Tissue Diseases

Age range

20 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Local Institution

Morrisville, North Carolina, 27560, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosis of moderate-to-severe Psoriasis (PsO) by physician (phase 1) or self-reported (phase 2)
  • Currently taking systemic psoriasis treatment
  • Japanese resident aged 20 years and older

Exclusion criteria

  • Unable or unwilling to provide informed consent
  • Diagnosis of guttate, inverse, pustular, erythrodermic, or drug-induced psoriasis

Treatment and study plan

Primary outcomes

  1. Psoriasis (PsO) patient preferences of moderate-to-severe systemic treatment atrribute

    Time frame: Within 60 minutes of survey/interview

  2. Distribution of socio-demographic characteristics of Psoriasis (PsO) participants in Phase 1: Sex

    Time frame: At Baseline

  3. Distribution of socio-demographic characteristics of PsO participants in Phase 1: Age

    Time frame: At Baseline

  4. Distribution of clinical characteristics of PsO participants in Phase 1: Time since PsO diagnosis

    Time frame: At Baseline

  5. Distribution of clinical characteristics of PsO participants in Phase 1: Severity of PsO

    Time frame: At Baseline

  6. Distribution of clinical characteristics of PsO participants in Phase 1: Current treatments for PsO

    Time frame: At Baseline

  7. Distribution of clinical characteristics of PsO participants in Phase 1: Time on current PsO treatment

    Time frame: At Baseline

  8. Distribution of socio-demographic characteristics of PsO participants in Phase 1: Residence

    Time frame: At Baseline

  9. Distribution of socio-demographic characteristics of PsO participants in Phase 1: Employment status

    Time frame: At Baseline

  10. Distribution of socio-demographic characteristics of PsO participants in Phase 1: Education

    Time frame: At Baseline

  11. Distribution of clinical characteristics of PsO participants in Phase 1: Total number of previous treatments

    Time frame: At Baseline

  12. Distribution of clinical characteristics of PsO participants in Phase 1: Previous treatments for PsO

    Time frame: At Baseline

  13. Distribution of socio-demographic characteristics of PsO participants in Phase 1: Level of income

    Time frame: At Baseline

  14. Distribution of socio-demographic characteristics of Psoriasis (PsO) participants in Phase 2: Sex

    Time frame: At Baseline

  15. Distribution of socio-demographic characteristics of Psoriasis (PsO) participants in Phase 2: Age

    Time frame: At Baseline

  16. Distribution of socio-demographic characteristics of Psoriasis (PsO) participants in Phase 2: Height

    Time frame: At Baseline

  17. Distribution of socio-demographic characteristics of Psoriasis (PsO) participants in Phase 2: Weight

    Time frame: At Baseline

  18. Distribution of socio-demographic characteristics of Psoriasis (PsO) participants in Phase 2: Residence

    Time frame: At Baseline

  19. Distribution of socio-demographic characteristics of Psoriasis (PsO) participants in Phase 2: Employment status

    Time frame: At Baseline

  20. Distribution of socio-demographic characteristics of Psoriasis (PsO) participants in Phase 2: Type of occupation

    Time frame: At Baseline

  21. Distribution of socio-demographic characteristics of Psoriasis (PsO) participants in Phase 2: Education

    Time frame: At Baseline

  22. Distribution of clinical characteristics of Psoriasis (PsO) participants in Phase 2: Time since PsO diagnosis

    Time frame: At Baseline

  23. Distribution of clinical characteristics of Psoriasis (PsO) participants in Phase 2: Self-reported severity

    Time frame: At Baseline

  24. Distribution of clinical characteristics of Psoriasis (PsO) participants in Phase 2: Current treatments for PsO

    Time frame: At Baseline

  25. Distribution of clinical characteristics of Psoriasis (PsO) participants in Phase 2: Time on current PsO treatment

    Time frame: At Baseline

  26. Distribution of clinical characteristics of Psoriasis (PsO) participants in Phase 2: Previous treatments for PsO

    Time frame: At Baseline

  27. Distribution of clinical characteristics of Psoriasis (PsO) participants in Phase 2: Comorbid conditions of interest

    Time frame: At Baseline

  28. Distribution of socio-demographic characteristics of Psoriasis (PsO) participants in Phase 2: Level of income

    Time frame: At Baseline

Sponsors and collaborators

Lead sponsor

Bristol-Myers Squibb

Industry

Registry information

Official study title

Patient Preference for Treatment of Moderate-To-Severe Psoriasis in Japan

Acronym: DCE

Important dates

Study start
2021
Primary completion
2022
Study completion
2022
First posted
Oct 4, 2021
Registry last updated
Jun 6, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.